Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03935971 · ClinicalTrials.gov registry record · Phase 4
The Effects of Dupilumab on Allergic Contact Dermatitis
A Phase 4 study of Allergic Contact Dermatitis, sponsored by Brigham and Women's Hospital.
- Active
- Registry status
- Phase 4
- Development phase
- 17
- Enrollment target
- 1
- Study location
NCT03935971: Active Phase 4 study of Allergic Contact Dermatitis, sponsored by Brigham and Women's Hospital.
NCT03935971 is a Phase 4 study of Allergic Contact Dermatitis that is active but no longer recruiting, run by Brigham and Women's Hospital. The registered enrollment target is 17 participants, below the 26-participant average among 3 other Allergic Contact Dermatitis trials with a reported enrollment target (35% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03935971, a Phase 4 study of Allergic Contact Dermatitis, is active but no longer recruiting, sponsored by Brigham and Women's Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 17 participants
- Enrollment target
- 1
- Study location
Study Summary
The aim of this study is to investigate the effects of dupilumab on allergic contact dermatitis.
Primary Outcome
The investigator's global assessment is a physician-reported global assessment of disease activity (range 0-4) with 0 being clear and 4 being severe.
Conditions Studied
Interventions
- DRUG Dupilumab
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital, Department of Dermatology - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2019-12-18 |
| Est. Completion | 2026-07-31 |
| Phase | Phase 4 |
What the registry record for NCT03935971 still lists
NCT03935971 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 26-participant average among 3 other Allergic Contact Dermatitis trials with a reported enrollment target (35% lower).
The record links to 1 condition, with Allergic Contact Dermatitis appearing as the primary indexed condition, and to 1 intervention - of which Dupilumab is the first listed.
NCT03935971 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03935971 about?
NCT03935971 is a clinical study titled "The Effects of Dupilumab on Allergic Contact Dermatitis". The aim of this study is to investigate the effects of dupilumab on allergic contact dermatitis.
What is the current status of trial NCT03935971?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 17 participants. The study started on 2019-12-18. Estimated completion is 2026-07-31.
What conditions does trial NCT03935971 study?
This clinical trial studies the following conditions: Allergic Contact Dermatitis.
What interventions are being tested in trial NCT03935971?
The interventions under investigation include: Dupilumab (DRUG).
Who is sponsoring clinical trial NCT03935971?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03935971 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Allergic Contact Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation
RECRUITING · Phase 2
-
Study of Apremilast in Atopic or Contact Dermatitis
COMPLETED · Phase 2
-
Efficacy of Baricitinib In Treatment of Delayed-Type Hypersensitivity Versus Irritant Skin Reactions in Healthy Adult Male Subjects
COMPLETED · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI